Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER versus CEFZIL.
CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER vs CEFZIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Cefprozil inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking.
750 mg to 1.5 g intravenously every 8 hours; for severe infections, up to 1.5 g every 6 hours.
500 mg orally twice daily for 10 days; for uncomplicated skin infections, 250 mg twice daily or 500 mg once daily.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.6 hours (prolonged to 15-22 hours in severe renal impairment, CrCl <10 mL/min); requires dose adjustment in renal failure
1.2-1.5 hours in healthy adults; prolonged in renal impairment (e.g., up to 6-8 hours in severe renal failure)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; fecal: <1%
Renal: 80-91% unchanged in urine; biliary/fecal: minimal (<5%)
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic